At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 173 enrolled
Drug / intervention
Belatacept +2 moredrug
Likely dose
Belatacept 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Belatacept Conversion Trial in Renal Transplantation
In Brief
A Phase 2 clinical trial evaluating Belatacept, Cyclosporine A, and 1 other intervention for Renal Transplant. Completed, enrolled 173 participants across 44 sites in 12 countries.
Detailed Summary
The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant
CountriesArgentina, Australia, Belgium, Brazil, Canada, France, Germany, India, Mexico, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartJan 2007
Primary CompletionJun 2009
Study CompletionJun 2013
TodayJul 2026
First PostedNov 22, 2006
Enrollment StartJan 1, 2007
Primary CompletionJun 1, 2009
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.6 years ago
Interventions
Belataceptdrug
IV, IV Infusion, 5 mg/kg once every 28 days for one year
Cyclosporine Adrug
Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
Tacrolimusdrug
Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year